IDEXX Laboratories (IDXX) Hisse Fiyat
IDEXX Laboratories Fiyat
IDEXX Laboratories, son 19 yılda gelirini yıllık %9,7 artırarak 4,30 Md USD seviyesine taşıdı. Hisse başına kâr, son 19 yılda yıllık %16,2 büyüdü. IDEXX Laboratories için net marj, %24,6 ile birkaç yıl önceki %23,2 seviyesine göre yükseldi. IDEXX Laboratories için 12 aylık konsensüs fiyat hedefi 665,00 USD; bu, hissenin bugünkü fiyatının yaklaşık %19,5 üzerinde bir seviyeye denk geliyor. 22 analistten 14 tanesi hisse için alım öneriyor — genel konsensüs: Al.
IDEXX Laboratories hisse senedi fiyatı
Bu verilere Eulerpool API üzerinden ulaşın
Ayda 100.000 ücretsiz istek · kredi kartı yok
IDEXX Laboratories iş modeli ve hisse analizi
IDEXX Laboratories hakkında sık sorulan sorular
IDEXX Laboratories Inc is a global leader in veterinary diagnostics and software solutions. Their business model revolves around providing innovative products and services to veterinary practices, livestock producers, and pharmaceutical companies. IDEXX offers a wide range of diagnostic tests, instruments, and consumables that aid in the detection and prevention of diseases in animals. Their software solutions enable veterinary practices to streamline their operations, manage patient data, and enhance overall patient care. With a strong focus on research and development, IDEXX continuously strives to introduce advanced technologies and improve the quality of veterinary care worldwide.
IDEXX Laboratories Inc is primarily active in the animal health industry.
The main competitors of IDEXX Laboratories Inc in the market are Zoetis Inc, Heska Corporation, and Abaxis, Inc.
IDEXX Laboratories Inc. is a leading global company in veterinary diagnostics and software solutions. Founded in 1983, IDEXX has built a strong reputation for offering innovative products and services to support the animal healthcare industry. The company's mission is to improve the health and well-being of pets, livestock, and wildlife. IDEXX provides a wide range of diagnostic tests, instruments, and digital imaging systems that help veterinarians accurately diagnose diseases and ensure the best possible care for animals. With its headquarters in Maine, USA, IDEXX has an extensive network of customers worldwide. As a pioneer in animal diagnostics, IDEXX continues to drive advancements in veterinary medicine and enhance animal healthcare globally.
IDEXX Laboratories Inc, a renowned leader in veterinary diagnostics and software, has achieved numerous significant milestones over the years. The company pioneered the first veterinary reference laboratory, revolutionizing the field of animal health diagnostics. IDEXX also developed innovative technologies such as the SNAP test, providing immediate results for veterinarians. Furthermore, the company introduced groundbreaking products like the IDEXX ProCyte Dx Hematology Analyzer, enhancing the accuracy and efficiency of pet healthcare. With a commitment to continuous innovation, IDEXX Laboratories Inc has consistently redefined the standards in veterinary medicine, offering exceptional diagnostic solutions for veterinarians globally.
IDEXX Laboratories Inc is primarily present in various countries and regions worldwide. As a leading veterinary diagnostics and software provider, IDEXX operates in over 175 countries. Its operations span across North America, including the United States and Canada, as well as Europe, Asia-Pacific, Latin America, and the Middle East. With a strong global presence, IDEXX consistently delivers innovative solutions and services to veterinary practices, animal healthcare professionals, and laboratories around the globe.
IDEXX Laboratories Inc represents strong values and a clear corporate philosophy. The company's values are centered around innovation, integrity, and collaboration. IDEXX is committed to continuously developing innovative diagnostic solutions to improve the health and well-being of animals worldwide. They uphold the highest standards of integrity in their business practices, ensuring transparency and trust with their customers and partners. Additionally, IDEXX promotes a culture of collaboration, fostering a diverse and inclusive environment that encourages teamwork and supports the growth and success of its employees. Through these values and corporate philosophy, IDEXX Laboratories Inc exemplifies its dedication to advancing animal healthcare globally.
Analistler şu anda IDEXX Laboratories hissesi için ortalama 665,00 USD hedef fiyat belirliyor (medyan: 665,00 USD); bu, son fiyata göre +19,5 % anlamına gelir. Konsensüs 22 analist notuna dayanır.
22 analist şu anda IDEXX Laboratories hissesini değerlendiriyor: 14 al, 8 tut, 0 sat öneriyor. 2026 için analistler IDEXX Laboratories şirketinin 4,72 Md USD gelir ve 14,82 USD hisse başına kâr üretmesini bekliyor.
Güncel döviz kuruyla IDEXX Laboratories hissesi 495,53 EUR (556,30 USD) seviyesindedir.
IDEXX Laboratories hissesi (IDXX) 9 borsada işlem görür, bunlar arasında: NASDAQ (IDXX), London (0J8P.L), SIX (Zürich) (IX1.SW), XETRA (IX1.DE), Frankfurt (IX1.F), München (IX1.MU), Düsseldorf (IX1.DU), Wien (IDXX.VI).
IDEXX Laboratories Inc is a leading company in the field of animal health diagnostics and biotechnology. The company's business model is to offer innovative solutions to veterinarians, pet owners, and animal caretakers to improve the health and well-being of animals. IDEXX is divided into three main divisions: diagnostics and software, water testing, and animal genetics. Each division offers specialized products and services to meet the individual needs and requirements of customers. The diagnostics and software division of IDEXX offers a wide range of tests and instruments for the diagnosis of diseases in animals. The products range from simple blood tests to complex pathological examinations. IDEXX Labs specializes in tests for dogs, cats, and horses, offering a wide range of diagnostic options for these animals. The company also works closely with veterinarians and veterinary clinics to provide a wide range of diagnostic and laboratory services. In the water testing division, the company develops solutions for the detection of contaminants in drinking water and bottled water. This area of the business is focused on companies and government agencies that monitor the condition of water and want to ensure that it is safe for consumption. The animal genetics division of IDEXX offers breeding programs and tests for animals. The foundation of this division's work is DNA sequencing, which allows for the identification of genetic factors that can impact the health and behavior of animals. The animal genetics department works with veterinarians and pet owners to provide customer-oriented services that contribute to the improvement of animal health and breed. IDEXX is committed to providing its customers with innovative and advanced solutions. The company continuously invests in research and development to bring new products to the market and improve its existing offerings. IDEXX's business model is based on creating value by helping veterinarians and animal caretakers improve the health, well-being, and quality of life of animals. IDEXX also aims to integrate its products and services into the online market. To achieve this, the company develops various software solutions to ensure better portability and convenient connections to its services for customers. IDEXX is already involved in telemedicine, offering pet owners the opportunity to speak with veterinarians online and receive diagnoses. Overall, IDEXX's business model is focused on providing a comprehensive platform for animal health and biotechnology. Through its divisions in diagnostics, water testing, and animal genetics, the company has developed a wide range of products and solutions aimed at improving the health and well-being of animals and providing customers with high value.
beklenen'nin IDEXX Laboratories hasılatı 4,72 Md USD'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.
beklenen'nin IDEXX Laboratories karı 1,20 Md USD'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.
IDEXX Laboratories'nin Fiyat/Kazanç (F/K) oranı şu anda 37,53'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların IDEXX Laboratories hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.
IDEXX Laboratories'nin Fiyat/Satış (F/S) oranı şu anda 9,51'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve IDEXX Laboratories hisse senedinin değerleme metriği olarak hizmet eder.
IDEXX Laboratories'nin Eulerpool Kalite Puanı 8/10'dur.
IDEXX Laboratories'nin ISIN'i US45168D1046'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.
IDEXX Laboratories'nin WKN'i 888210'dir. WKN (Wertpapierkennnummer), menkul kıymetleri tanımlamak için kullanılan altı haneli bir Alman kimlik numarasıdır.
IDEXX Laboratories'nin ticker'ı IDXX'dir. Ticker sembolü, IDEXX Laboratories hisseleri borsada işlem görmek için kullanılır.
IDEXX Laboratories Hissesi
IDEXX Laboratories Emsaller Grubu
IDEXX Laboratories Ticker
IDEXX Laboratories FIGI
IDEXX Laboratories'nin tüm temel göstergeleri ve derinlemesine analizi
IDEXX Laboratories hissesine yönelik aktienanalizimiz, satış, kar, P/E oranı, P/S oranı, EBIT gibi önemli mali kriterleri içermekte olup, dividende bilgilerini de ele almaktadır. Ayrıca, hisseler, piyasa değeri, borçlar, özsermaye ve IDEXX Laboratories şirketin yükümlülükleri gibi konuları incelemekteyiz. Bu konular hakkında daha detaylı bilgilere ihtiyacınız varsa, web sitemizin alt sayfalarında kapsamlı analizler sunuyoruz: